Register Now

Acknowledgements

ILCA 2019 / Partners & Exhibitors / Acknowledgements
ILCA warmly thanks all Partners and Sponsors for their unrestricted support to the 2019 Annual Conference and their commitment to help advance liver cancer science.

Diamond Partner

Bayer

Bayer is committed to delivering SCIENCE FOR A BETTER LIFE by advancing a portfolio of innovative treatments. In just over a decade, the advancing oncology portfolio at Bayer has expanded significantly and includes four marketed products, as well as several investigational compounds in clinical development. We are driven every day by what matters most to the cancer community and work hard to transform the lives of people impacted by cancer, fueled by science and innovation.

Platinum Partner

Eisai

At Eisai Inc., human health care is our goal. We give our first thoughts to patients and their families and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to help address unmet medical needs.

In March 2018, Eisai and Merck, known as MSD outside the U.S. and Canada, through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of LENVIMA® (lenvatinib). Under the agreement, the companies will jointly develop and commercialize LENVIMA®, both as monotherapy and in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab).

To learn more, visit www.eisai.com/US.

Gold Partners

Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company focused on discovering, developing and delivering innovative medicines for patients with serious diseases. We are focused on helping patients in disease areas including oncology, cardiovascular, immunoscience and fibrosis. Each day, our employees work together for patients – it drives everything we do.

BTG Interventional Oncology

BTG Interventional Oncology is transforming the cancer care with smarter solutions. Our treatments include elegant and innovative new medicines, improved device technology and ground-breaking delivery techniques. Healthcare is evolving and we believe intelligent science is the way forward.
To learn more about BTG Interventional Oncology, please visit: btg-io.com.

Exelixis

Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. For more information about Exelixis, please visit www.exelixis.com, follow @ExelixisInc on Twitter or like Exelixis, Inc. on Facebook.

Lilly

For more than 50 years, Lilly has been dedicated to delivering life-changing medicines and support to people living with cancer and those who care for them. Lilly is determined to build on this heritage and continue making life better for all those affected by cancer around the world. To learn more about Lilly’s commitment to people with cancer, please visit www.LillyOncology.com.

Exhibitors

Genentech

For more than 40 years, we’ve been following the science, seeking solutions to unmet medical needs. As a proud member of the Roche Group, we make medicines to treat patients with serious medical conditions. We are headquartered in South San Francisco, CA, USA.

Media Partners

Contact Us

Keep Me Updated

By continuing to browse this website, you accept cookies which are used to offer a personalized experience on our website, generate statistics and realize advertising or social network tracking. Find out more about our Privacy & Cookie policy and how to manage them on your browser. You can change your cookie settings at any time. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close